{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:01:17Z","timestamp":1781740877962,"version":"3.54.5"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2014,9,3]],"date-time":"2014-09-03T00:00:00Z","timestamp":1409702400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1007\/s00213-014-3723-y","type":"journal-article","created":{"date-parts":[[2014,9,2]],"date-time":"2014-09-02T02:33:30Z","timestamp":1409625210000},"page":"907-915","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice"],"prefix":"10.1007","volume":"232","author":[{"given":"Edgardo","family":"Falcon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlyn","family":"Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivon A.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany E.","family":"Hill-Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irwin","family":"Lucki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,9,3]]},"reference":[{"key":"3723_CR1","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2147\/PPA.S29716","volume":"6","author":"KS Al-Harbi","year":"2012","unstructured":"Al-Harbi KS (2012) Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Pref Adherence 6:369\u2013388","journal-title":"Patient Pref Adherence"},{"key":"3723_CR2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s002130100704","volume":"155","author":"CM Andrews","year":"2001","unstructured":"Andrews CM, Lucki I (2001) Effects of cocaine on extracellular dopamine and serotonin levels in the nucleus accumbens. Psychopharmacology 155:221\u2013229","journal-title":"Psychopharmacology"},{"key":"3723_CR3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature10130","volume":"475","author":"AE Autry","year":"2011","unstructured":"Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, Kavalali ET, Monteggia LM (2011) NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475:91\u201395","journal-title":"Nature"},{"key":"3723_CR4","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1038\/npp.2008.234","volume":"34","author":"DT Balu","year":"2009","unstructured":"Balu DT, Hodes GE, Anderson BT, Lucki I (2009) Enhanced sensitivity of the MRL\/MpJ mouse to the neuroplastic and behavioral effects of chronic antidepressant treatments. Neuropsychopharm 34:1764\u20131773","journal-title":"Neuropsychopharm"},{"key":"3723_CR5","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1038\/sj.npp.1301616","volume":"33","author":"AJ Bechtolt","year":"2008","unstructured":"Bechtolt AJ, Valentino RJ, Lucki I (2008) Overlapping and distinct brain regions associated with the anxiolytic effects of chlordiazepoxide and chronic fluoxetine. Neuropsychopharmacology 33:2117\u20132130","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"3723_CR6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00004714-199502000-00008","volume":"15","author":"JA Bodkin","year":"1995","unstructured":"Bodkin JA, Zornberg GL, Lukas SE, Cole JO (1995) Buprenorphine treatment of refractory depression. J Clin Psychopharmacol 15(1):49\u201357","journal-title":"J Clin Psychopharmacol"},{"key":"3723_CR7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00213-002-1155-6","volume":"163","author":"F Borsini","year":"2002","unstructured":"Borsini F, Podhorna J, Marazziti D (2002) Do animal models of anxiety predict anxiolytic-like effects of antidepressants? Psychopharmacology 163:121\u2013141","journal-title":"Psychopharmacology"},{"key":"3723_CR8","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1097\/ALN.0b013e318238fea0","volume":"115","author":"SM Brown","year":"2011","unstructured":"Brown SM, Holtzman M, Kim T, Kharasch ED (2011) Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active. Anesthesiology 115:1251\u20131260","journal-title":"Anesthesiology"},{"key":"3723_CR9","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00213-010-1832-9","volume":"210","author":"GV Carr","year":"2010","unstructured":"Carr GV, Lucki I (2010) Comparison of the kappa opioid receptor antagonist DIPPA in tests of anxiety-like behavior between Wistar Kyoto and Sprague Dawley rats. Psychopharmacology 210:295\u2013302","journal-title":"Psychopharmacology"},{"key":"3723_CR10","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/npp.2009.183","volume":"35","author":"GV Carr","year":"2010","unstructured":"Carr GV, Bangasser DA, Bethea T, Young M, Valentino RJ, Lucki I (2010) Antidepressant-like effects of kappa-opioid receptor antagonists in Wistar Kyoto rats. Neuropsychopharmacology 35:752\u2013763","journal-title":"Neuropsychopharmacology"},{"key":"3723_CR11","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/S0140-6736(09)60046-5","volume":"373","author":"A Cipriani","year":"2009","unstructured":"Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C (2009) Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373:746\u2013758","journal-title":"Lancet"},{"key":"3723_CR12","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/ADM.0b013e31806c9202","volume":"1","author":"A Cowan","year":"2007","unstructured":"Cowan A (2007) Buprenorphine: the basic pharmacology revisited. J Addict Med 1:68\u201372","journal-title":"J Addict Med"},{"key":"3723_CR13","volume-title":"Buprenorphine: combating drug abuse with a unique opioid","year":"1995","unstructured":"Cowan A, Lewis JW (eds) (1995) Buprenorphine: combating drug abuse with a unique opioid. Wiley-Liss, New York"},{"key":"3723_CR14","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.pbb.2004.03.014","volume":"78","author":"JJ Crowley","year":"2004","unstructured":"Crowley JJ, Jones MD, O\u2019Leary OF, Lucki I (2004) Automated tests for measuring the effects of antidepressants in mice. Pharmacol Biochem Behav 78:269\u2013274","journal-title":"Pharmacol Biochem Behav"},{"issue":"11","key":"3723_CR15","doi-asserted-by":"crossref","first-page":"963","DOI":"10.4088\/JCP.v63n1102","volume":"63","author":"WH Crown","year":"2002","unstructured":"Crown WH, Finkelstein S, Berndt ER, Ling D, Poret AW, Rush AJ, Russell JM (2002) The impact of treatment-resistant depression on health care utilization and costs. Clin Psychiatry 63(11):963\u2013971","journal-title":"Clin Psychiatry"},{"key":"3723_CR16","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/j.1476-5381.2011.01362.x","volume":"164","author":"JF Cryan","year":"2011","unstructured":"Cryan JF, Sweeney FF (2011) The age of anxiety: role of animal models of anxiolytic action in drug discovery. Br J Pharmacol 164:1129\u20131161","journal-title":"Br J Pharmacol"},{"key":"3723_CR17","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00213-005-0093-5","volume":"182","author":"JF Cryan","year":"2005","unstructured":"Cryan JF, Page ME, Lucki I (2005) Differential behavioral effects of the antidepressants reboxetine, fluoxetine, and moclobemide in a modified forced swim test following chronic treatment. Psychopharmacology 182:335\u2013344","journal-title":"Psychopharmacology"},{"key":"3723_CR18","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s002130051131","volume":"147","author":"A Dalvi","year":"1999","unstructured":"Dalvi A, Lucki I (1999) Murine models of depression. Psychopharmacology 147:14\u201316","journal-title":"Psychopharmacology"},{"issue":"6","key":"3723_CR19","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.suponc.2012.05.002","volume":"10","author":"MP Davis","year":"2012","unstructured":"Davis MP (2012) Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. J Support Oncol 10(6):209\u2013219","journal-title":"J Support Oncol"},{"key":"3723_CR20","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1037\/1064-1297.5.2.107","volume":"5","author":"MJ Detke","year":"1997","unstructured":"Detke MJ, Johnson J, Lucki I (1997) Acute and chronic antidepressant drug treatment in the rat forced swimming test model of depression. Exp Clin Psychopharmacol 5:107\u2013112","journal-title":"Exp Clin Psychopharmacol"},{"key":"3723_CR21","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S0022-3565(25)24578-5","volume":"244","author":"G DiChiara","year":"1988","unstructured":"DiChiara G, Imperato A (1988) Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J Pharmacol Exp Ther 244:1067\u20131080","journal-title":"J Pharmacol Exp Ther"},{"key":"3723_CR22","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.neubiorev.2005.03.017","volume":"29","author":"SC Dulawa","year":"2005","unstructured":"Dulawa SC, Hen R (2005) Recent advances in animal models of chronic antidepressant effects: the novelty-induced hypophagia test. Neurosci Biobehav Rev 29:771\u2013783","journal-title":"Neurosci Biobehav Rev"},{"key":"3723_CR23","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/sj.npp.1300433","volume":"29","author":"SC Dulawa","year":"2004","unstructured":"Dulawa SC, Holick KA, Gundersen B, Hen R (2004) Effects of chronic fluoxetine in animal models of anxiety and depression. Neuropsychopharmacology 29:1321\u20131330","journal-title":"Neuropsychopharmacology"},{"key":"3723_CR24","unstructured":"Ehrich E, Turncliff R, Sellers E, Jones R, Fava M (2012) Early clinical development of the opioid modulator ALKS 5461 in the treatment of depression. NCDEU"},{"key":"3723_CR25","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.euroneuro.2010.06.001","volume":"20","author":"L Fostick","year":"2010","unstructured":"Fostick L, Silberman A, Beckman M, Spivak B, Amital D (2010) The economic impact of depression: resistance or severity? Eur Neuropsychopharm 20:671\u2013675","journal-title":"Eur Neuropsychopharm"},{"key":"3723_CR26","volume-title":"The mouse brain in stereotaxic coordinates","author":"KBJ Franklin","year":"2004","unstructured":"Franklin KBJ, Paxinos G (2004) The mouse brain in stereotaxic coordinates. Academic, San Diego"},{"key":"3723_CR27","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00213-008-1112-0","volume":"198","author":"EM Glover","year":"2008","unstructured":"Glover EM, Davis M (2008) Anxiolytic-like effects of morphine and buprenorphine in the rat model of fear-potentiated startle: tolerance, cross-tolerance, and blockade by naloxone. Psychopharmacology 198:167\u2013180","journal-title":"Psychopharmacology"},{"key":"3723_CR28","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s005400170004","volume":"15","author":"M Gringauz","year":"2001","unstructured":"Gringauz M, Rabinowitz R, Stav A, Korczyn AD (2001) Tolerance to the analgesic effect of buprenorphine, butorphanol, nalbuphine, and cyclorphan, and cross-tolerance to morphine. J Anesth 15:204\u2013209","journal-title":"J Anesth"},{"key":"3723_CR29","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0022-3565(24)29586-0","volume":"297","author":"P Huang","year":"2001","unstructured":"Huang P, Kehner GB, Cowan A, Liu-Chen LY (2001) Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther 297:688\u2013695","journal-title":"J Pharmacol Exp Ther"},{"key":"3723_CR30","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.psyneuen.2012.05.002","volume":"38","author":"JC Ipser","year":"2013","unstructured":"Ipser JC, Terburg D, Syal S, Phillips N, Solms M, Paksepp J, Malcolm-Smith S, Thomas K, Stein DJ, van Honk J (2013) Reduced fear-recognition sensitivity following acute buprenorphine administration in healthy volunteers. Psychoneuroendocrinology 38:166\u2013170","journal-title":"Psychoneuroendocrinology"},{"key":"3723_CR31","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00213-010-2140-0","volume":"213","author":"J Jiao","year":"2011","unstructured":"Jiao J, Nitzke AM, Doukas DG, Seiglie MP, Dulawa SC (2011) Antidepressant response to chronic citalopram treatment in eight inbred mouse strains. Psychopharmacology 213:509\u2013520","journal-title":"Psychopharmacology"},{"key":"3723_CR32","doi-asserted-by":"crossref","unstructured":"Karp JF, Butters MA, Begley A, Miller MD, Lenze EJ, Blumberger D, Mulsant B, Reynolds III CF (2014) Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in mid-life and older adults. J Clin Psychiatry in press","DOI":"10.4088\/JCP.13m08725"},{"issue":"6","key":"3723_CR33","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1001\/archpsyc.62.6.617","volume":"62","author":"RC Kessler","year":"2005","unstructured":"Kessler RC, Chiu WT, Demier O, Merikangas KR, Walters EE (2005) Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62(6):617\u2013627","journal-title":"Arch Gen Psychiatry"},{"key":"3723_CR34","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0022-3565(24)29477-5","volume":"298","author":"DA Knobelman","year":"2001","unstructured":"Knobelman DA, Hen R, Lucki I (2001) Genetic regulation of extracellular serotonin by 5-hydroxytryptamine1A and 5-hydroxytryptamine1B autoreceptors in different brain regions of the mouse. J Pharmacol Exp Ther 298:1083\u20131091","journal-title":"J Pharmacol Exp Ther"},{"key":"3723_CR35","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1124\/jpet.107.127415","volume":"323","author":"AT Knoll","year":"2007","unstructured":"Knoll AT, Meloni EG, Thomas JB, Carroll FI, Carlezon WA (2007) Anxiolytic-like effects of kappa opioid receptor antagonists in models of unlearned and learned fear in rats. J Pharmacol Exp Ther 323:838\u2013845","journal-title":"J Pharmacol Exp Ther"},{"key":"3723_CR36","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.biopsych.2011.03.017","volume":"70","author":"AT Knoll","year":"2011","unstructured":"Knoll AT, Muschamp JW, Sillivan SE, Ferguson D, Dietz DM, Meloni EG, Carroll FI, Nestler EJ, Konradi C, Carlezon WA (2011) Kappa opioid receptor signaling in the basolateral amygdala regulates conditioned fear and anxiety in rats. Biol Psychiatry 70:425\u2013433","journal-title":"Biol Psychiatry"},{"key":"3723_CR37","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0740-5472(90)90035-O","volume":"7","author":"TR Kosten","year":"1990","unstructured":"Kosten TR, Morgan C, Kosten TA (1990) Depressive symptoms during buprenorphine treatment of opioid abusers. J Subst Abuse Treat 7:51\u201354","journal-title":"J Subst Abuse Treat"},{"key":"3723_CR38","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/0028-3908(87)90112-2","volume":"26","author":"DJ Leander","year":"1987","unstructured":"Leander DJ (1987) Buprenorphine has potent kappa opioid receptor antagonist activity. Neuropharmacology 26:1445\u20131447","journal-title":"Neuropharmacology"},{"key":"3723_CR39","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.drugalcdep.2006.03.017","volume":"85","author":"V Lelong-Boulouard","year":"2006","unstructured":"Lelong-Boulouard V, Quentin T, Moreaux F, Debruyne D, Boulouard M, Coquerel A (2006) Interactions of buprenorphine and dipotassium clorazepate on anxiety and memory functions in the mouse. Drug Alcohol Depen 85:103\u2013113","journal-title":"Drug Alcohol Depen"},{"key":"3723_CR40","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002130100694","volume":"155","author":"I Lucki","year":"2001","unstructured":"Lucki I, Dalvi A, Mayorga AJ (2001) Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice. Psychopharmacology 155:315\u2013322","journal-title":"Psychopharmacology"},{"key":"3723_CR41","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2174\/1570159043359477","volume":"2","author":"K Lufty","year":"2004","unstructured":"Lufty K, Cowan A (2004) Buprenorphine: a unique drug with complex pharmacology. Curr Neuropharmacol 2:395\u2013402","journal-title":"Curr Neuropharmacol"},{"issue":"3","key":"3723_CR42","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.tins.2012.11.002","volume":"36","author":"PE Lutz","year":"2013","unstructured":"Lutz PE, Kieffer BL (2013) Opioid receptors: distinct roles in mood disorders. Trends Neurosci 36(3):195\u2013206","journal-title":"Trends Neurosci"},{"key":"3723_CR43","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1124\/jpet.102.046433","volume":"305","author":"SD Mague","year":"2003","unstructured":"Mague SD, Pliakas AM, Todtenkopf MS, Tomasiewicz HC, Zhang Y, Stevens WC Jr, Jones RM, Portoghese PS, Carlezon WA (2003) Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats. J Pharmacol Exp Ther 305:323\u2013330","journal-title":"J Pharmacol Exp Ther"},{"key":"3723_CR44","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0304-3940(94)90559-2","volume":"181","author":"IM Maisonneuve","year":"1994","unstructured":"Maisonneuve IM, Archer S, Glick SD (1994) U50,488, a kappa opioid receptor agonist, attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats. Neurosci Lett 181:57\u201360","journal-title":"Neurosci Lett"},{"key":"3723_CR45","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.neuropharm.2007.01.005","volume":"52","author":"P Marquez","year":"2007","unstructured":"Marquez P, Ballram R, Kieffer BL, Lufty K (2007) The mu opioid receptor is involved in buprenorphine-induced locomotor stimulation and conditioned place preference. Neuropharmacology 52:1336\u20131341","journal-title":"Neuropharmacology"},{"key":"3723_CR46","doi-asserted-by":"crossref","first-page":"5674","DOI":"10.1523\/JNEUROSCI.23-13-05674.2003","volume":"23","author":"JP McLaughlin","year":"2003","unstructured":"McLaughlin JP, Marton-Popovici M, Chavkin C (2003) Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses. J Neurosci 23:5674\u20135683","journal-title":"J Neurosci"},{"key":"3723_CR47","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/sj.npp.1300860","volume":"31","author":"JP McLaughlin","year":"2006","unstructured":"McLaughlin JP, Li S, Valdez J, Chavkin TA, Chavkin C (2006) Social defeat stress-induced behavioral responses are mediated by the endogenous kappa opioid system. Neuropsychopharmacology 31:1241\u20131248","journal-title":"Neuropsychopharmacology"},{"key":"3723_CR48","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.biopsych.2012.06.022","volume":"74","author":"JW Murrough","year":"2013","unstructured":"Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, aan het Rot M, Collins KA, Mathew SJ, Charney DS, Iosifescu DV (2013) Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 74:250\u2013256","journal-title":"Biol Psychiatry"},{"issue":"5","key":"3723_CR49","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/JCP.0b013e31818638a4","volume":"28","author":"PW Nyhuis","year":"2008","unstructured":"Nyhuis PW, Gastpar M, Scherbaum N (2008) Opiate treatment in depression refractory to antidepressants and electroconvulsive therapy. J Clin Psychopharmacol 28(5):593\u2013595","journal-title":"J Clin Psychopharmacol"},{"key":"3723_CR50","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1124\/jpet.110.173823","volume":"336","author":"CA Paronis","year":"2011","unstructured":"Paronis CA, Bergman J (2011) Buprenorphine and opioid antagonism, tolerance, and naltrexone-precipitated withdrawal. J Pharmacol Exp Ther 336:488\u2013495","journal-title":"J Pharmacol Exp Ther"},{"key":"3723_CR51","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1023\/A:1016340106299","volume":"2","author":"ML Richards","year":"1985","unstructured":"Richards ML, Sadee W (1985) Buprenorphine is an antagonist at the kappa opioid receptor. Pharmacol Res 2:178\u2013181","journal-title":"Pharmacol Res"},{"key":"3723_CR52","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1111\/j.1471-4159.2004.02589.x","volume":"90","author":"Y Shirayama","year":"2004","unstructured":"Shirayama Y, Ishida H, Iwata M, Hazama GI, Kawahara R, Duman RS (2004) Stress increases dynorphin immunoreactivity in limbic brain regions and dynorphin antagonism produces antidepressant-like effects. J Neurochem 90:1258\u20131268","journal-title":"J Neurochem"},{"key":"3723_CR53","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.drugalcdep.2011.01.017","volume":"117","author":"S Shmygalev","year":"2011","unstructured":"Shmygalev S, Damm M, Weckbecker K, Berghaus G, Petzke F, Sabatowski R (2011) The impact of long-term maintenance treatment with buprenorphine on complex psychomotor and cognitive function. Drug Alcohol Depend 117:190\u2013197","journal-title":"Drug Alcohol Depend"},{"key":"3723_CR54","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/10550880802122646","volume":"27","author":"PL Tenore","year":"2008","unstructured":"Tenore PL (2008) Psychotherapeutic benefits of opioid agonist therapy. J Addict Dis 27:49\u201365","journal-title":"J Addict Dis"},{"key":"3723_CR55","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00213-013-3195-5","volume":"229","author":"A Veer Van\u2019t","year":"2013","unstructured":"Van\u2019t Veer A, Carlezon WA (2013) Role of kappa-opioid receptors in stress and anxiety-related behavior. Psychopharmacology 229:435\u2013452","journal-title":"Psychopharmacology"},{"key":"3723_CR56","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.neulet.2005.02.026","volume":"381","author":"ADE Zomkowski","year":"2005","unstructured":"Zomkowski ADE, Santos ARS, Rodrigues ALS (2005) Evidence for the involvement of the opioid system in the agmatine antidepressant-like effect in the forced swimming test. Neurosci Lett 381:279\u2013283","journal-title":"Neurosci Lett"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-014-3723-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-014-3723-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-014-3723-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T12:28:57Z","timestamp":1746361737000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-014-3723-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,3]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["3723"],"URL":"https:\/\/doi.org\/10.1007\/s00213-014-3723-y","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,3]]}}}